These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 36949949)

  • 81. [Adoptive therapy with TCR gene-modified T cells for hematological malignancies and solid tumors].
    Ikeda H
    Rinsho Ketsueki; 2019; 60(6):716-722. PubMed ID: 31281165
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
    Yu T; Yu SK; Xiang Y; Lu KH; Sun M
    Front Immunol; 2022; 13():936496. PubMed ID: 35903099
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Hurdles to breakthrough in CAR T cell therapy of solid tumors.
    Marofi F; Achmad H; Bokov D; Abdelbasset WK; Alsadoon Z; Chupradit S; Suksatan W; Shariatzadeh S; Hasanpoor Z; Yazdanifar M; Shomali N; Khiavi FM
    Stem Cell Res Ther; 2022 Apr; 13(1):140. PubMed ID: 35365241
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes.
    Korell F; Berger TR; Maus MV
    Med; 2022 Aug; 3(8):538-564. PubMed ID: 35963235
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Adoptive CD8
    Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
    Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
    Miao L; Zhang Z; Ren Z; Tang F; Li Y
    Front Immunol; 2021; 12():687822. PubMed ID: 34093592
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
    Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
    J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors.
    Adachi K; Tamada K
    Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Development of Novel Gene-Modified T-Cell Therapies(CAR-T, TCR-T)].
    Kitano S
    Gan To Kagaku Ryoho; 2023 Oct; 50(10):1032-1037. PubMed ID: 38035829
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [CAR-T Cells in solid tumours: present and future].
    Ben Aïssa A; Niculescu MV; Migliorini D
    Rev Med Suisse; 2021 May; 17(739):985-993. PubMed ID: 34009758
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies.
    Matsueda S; Chodon T; Koya RC
    Adv Exp Med Biol; 2019; 1143():217-229. PubMed ID: 31338822
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
    Curran KJ; Pegram HJ; Brentjens RJ
    J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Advances and Challenges of CAR T Cells in Clinical Trials.
    Holzinger A; Abken H
    Recent Results Cancer Res; 2020; 214():93-128. PubMed ID: 31473850
    [TBL] [Abstract][Full Text] [Related]  

  • 96. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
    Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
    Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023.
    Sun MY; Li W; Chen W
    Hum Vaccin Immunother; 2023 Aug; 19(2):2251839. PubMed ID: 37814513
    [TBL] [Abstract][Full Text] [Related]  

  • 98. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Development of universal CAR-T cells].
    Kagoya Y; Hirano N
    Rinsho Ketsueki; 2022; 63(7):782-789. PubMed ID: 35922948
    [TBL] [Abstract][Full Text] [Related]  

  • 100. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.
    Feins S; Kong W; Williams EF; Milone MC; Fraietta JA
    Am J Hematol; 2019 May; 94(S1):S3-S9. PubMed ID: 30680780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.